| carfilzomib / Generic mfg. |
NCT00999414: UARK 2009-32 Compassionate Use Study of Carfilzomib |
|
|
| No Longer Available | N/A | | US | Carfilzomib | University of Arkansas, Onyx Therapeutics, Inc. | Multiple Myeloma | 04/15 | 04/15 | | |
NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease |
|
|
| Approved for marketing | N/A | | NA | Carfilzomib, Kyprolis® | Amgen, Multiple Myeloma Research Foundation | Multiple Myeloma | | | | |
| Withdrawn | N/A | 0 | Europe | | Universitaire Ziekenhuizen Leuven | Multiple Myeloma, Hematologic Diseases | 04/18 | 11/18 | | |
| Completed | N/A | 95 | US | | Vanderbilt University Medical Center, Takeda | Heart Failure, Multiple Myeloma | 07/19 | 07/19 | | |
NCT04137523: Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression |
|
|
| Recruiting | N/A | 100 | Europe | | University of Turin, Italy | Multiple Myeloma | 08/19 | 09/22 | | |
NCT03543579: Cardiovascular Complications of Carfilzomib Treatment |
|
|
| Active, not recruiting | N/A | 46 | Europe | | University of Athens | Multiple Myeloma | 10/19 | 12/21 | | |
NCT03776331: Vascular Functions in Myeloma Patients During Anti-tumor Therapy |
|
|
| Unknown status | N/A | 96 | NA | Flow mediated dilation | University Hospital, Essen | Cardiooncology, Myeloma, Endothelial Dysfunction | 12/19 | 03/20 | | |
NCT03091127: Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe |
|
|
| Completed | N/A | 705 | Europe, RoW | | Amgen | Multiple Myeloma | 03/20 | 03/20 | | |
NCT03724097: Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy |
|
|
| Active, not recruiting | N/A | 200 | US, RoW | RNA sequencing, RNA-seq, Transcriptome analysis, target drug with the score above 0,1, target drug with the score equal or below 0,1, non-target drug, palliative care | OmicsWay Corp., Oncobox Ltd, Vitamed LLC, N.N. Blokhin National Medical Research Center of Oncology, Kaluga Regional Clinical Oncology Center, Multidisciplinary medical holding SM-Clinic, Oncological Clinical Dispensary No. 1 of the Moscow City Health Department | Cancer | 04/21 | 11/22 | | |
NCT04004338: Carfilzomib in Combination for the Treatment of RR MM |
|
|
| Unknown status | N/A | 300 | RoW | Kyprolis | Black Sea Hematology Association, Amgen | Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma | 04/21 | 04/21 | | |
| Unknown status | N/A | 60 | Europe | | European Georges Pompidou Hospital | Myeloma, Heart Failure, Hypertension | 05/21 | 05/22 | | |
CARMYN, NCT04811508: Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Context of Carfilzomib Nominative Expanded Access and Compassionate Use |
|
|
| Completed | N/A | 172 | Europe | | Centre Hospitalier le Mans | Relapsed Multiple Myeloma | 12/21 | 12/21 | | |
NCT03375567: Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone |
|
|
| Completed | N/A | 28 | US | Guided Lesion Biopsies, Standard Lesion Biopsies | Yale University | Multiple Myeloma | 01/22 | 01/22 | | |
Carfil-HAD, NCT05041933: Secure Outsourcing of Carfilzomib in the Treatment of Multiple Myeloma to the Hospital at Home Setting |
|
|
| Recruiting | N/A | 20 | Europe | outsourcing of chemotherapy to Hospital at Home | University Hospital, Limoges | Hematological Diseases | 12/22 | 06/23 | | |
NCT03763370: Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma |
|
|
| Available | N/A | | NA | Belantamab mafodotin (GSK2857916) anti-BCMA-immunoconjugate | GlaxoSmithKline | Multiple Myeloma | | | | |
ADHOMY2, NCT05184595: Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib |
|
|
| Not yet recruiting | N/A | 52 | NA | Carfilzomib delivered in OH only, Carfilzomib delivered in OH and HaH combined | Central Hospital, Nancy, France | Multiple Myeloma | 03/23 | 10/24 | | |
NCT04827563: Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib |
|
|
| Recruiting | N/A | 50 | US | EndoPAT, Blood Pressure Cuff, Echocardiogram, Quality of Life Assessment, Blood Tests | University of Chicago | Multiple Myeloma, Shortness of Breath, Dyspnea, Cardiotoxicity | 08/26 | 08/26 | | |
NCT06463717: Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not |
|
|
| Recruiting | N/A | 210 | RoW | Transplant, Autologous, ASCT, Chemotherapy drug, Non ASCT regimen | First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, The Affiliated Hospital of Medical College, Ningbo University, Dongyang People's Hospital | Multiple Myeloma, Minimal Residual Disease | 11/28 | 12/28 | | |
NCT06203145: A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM |
|
|
| Recruiting | N/A | 30 | RoW | Bortezomib, Carfilzomib | Peking University First Hospital | Multiple Myeloma, Renal Injury | 11/25 | 11/25 | | |
NCT05620238: Home Treatment With Carfilzomib in Patients With Multiple Myeloma |
|
|
| Recruiting | N/A | 12 | Europe | Carfilzomib, Kyprolis | Thomas Lund | Multiple Myeloma | 12/24 | 05/25 | | |
NCT06409702: Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection |
|
|
| Not yet recruiting | N/A | 45 | NA | Carfilzomib, Kyprolis, Daratumumab, Darzalex, Lenalidomide, Dexamethasone, VRD for first-cycle induction therapy, Bortezomib(V), Lenalidomide(R), Dexamethasone(D) | The First Affiliated Hospital of Soochow University | Newly Diagnosed, High Risk, MRD, Multiple Myeloma | 09/27 | 12/27 | | |
CARO, NCT02970747: Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients |
|
|
| Active, not recruiting | N/A | 359 | Europe | Carfilzomib, Kyprolis® | iOMEDICO AG, Amgen | Multiple Myeloma in Relapse | 06/25 | 06/25 | | |
IONA-MM, NCT04458831: A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) |
|
|
| Recruiting | N/A | 1200 | Europe, Japan, US, RoW | isatuximab SAR650984, Sarclisa, Pomalidomide, Pomalyst, Dexamethasone, Carfilzomib | Sanofi | Plasma Cell Myeloma | 02/26 | 02/26 | | |
